Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

 

• Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity
• Topline data expected by end of calendar year 2024
• Additional studies under assessment for multiple metabolic conditions

https://www.prnewswire.com/news-releases/palatin-initiates-phase-2-clinical-study-of-bremelanotide-for-the-treatment-of-obesity-302170728.html